Amgen Inc. has announced that , its newest experimental ovarian cancer drug, trebananib, has failed in its medical trial stage at improving the survival rate of late-stage ovarian cancer patients. This anti-tumor treatment drug is designed to be administered together with paclitaxel, a chemotherapy drug. During the study’s Phase 3, doctor’s evaluated both the safety of administration and the … [Read more...]
Cervical Cancer Drug Approved by FDA
Avastin, the new drug developed for the treatment of several types of cancer has finally been approved for the treatment of cervical cancer in combination with chemotherapy by the Food and Drug Administration. Avastin (containing bevacizumab, monoclonal antibodies)is an angiogenesis inhibitor. It slows the development of new blood vessels that form in and feed tumors. While bevacizumab is … [Read more...]
Study links obesity with ovarian cancer
A new study has found a link between obesity and ovarian cancer. Obesity is the root cause of many lifestyle diseases that are leading to preventable deaths in US. In the past four decades, obesity rates in the US have soared, and kids ages six to 11 have been hit the hardest. The study says more the weight, higher is the rate for developing ovarian cancer in women. The study was conducted … [Read more...]